载脂蛋白 C-I 异构体与冠状动脉疾病患者相关。
Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease.
机构信息
Laboratory for Cardiovascular Chemistry, Department of Chemistry, Texas A&M University, College Station, TX 77843-3255, USA.
出版信息
Biochem Biophys Res Commun. 2011 Jan 28;404(4):1034-8. doi: 10.1016/j.bbrc.2010.12.105. Epub 2010 Dec 25.
Abstract
Apolipoprotein C-I (apoC-I) is a 6.6kDa serum protein associated with high density lipoproteins (HDL) and triglyceride-rich lipoproteins. In this study, apoC-I was examined in high density lipoprotein subfractions from individuals with and without coronary artery disease (CAD). New isoforms of apoC-I, were detected in the cohort of individuals with CAD using mass spectrometry while the expected apoC-I isoforms were absent. In addition, the apoC-I mass spectra for the CAD cohort had satellite peaks indicative of the involvement of oxidative processes. Further analysis of the mass spectra of the CAD and non-CAD cohorts suggest that the origin of these new isoforms may be due to genetic mutations that could compromise the function of apoC-I.
摘要
载脂蛋白 C-I（apoC-I）是一种 6.6kDa 的血清蛋白，与高密度脂蛋白（HDL）和富含甘油三酯的脂蛋白有关。在这项研究中，研究了患有和不患有冠状动脉疾病（CAD）的个体的高密度脂蛋白亚组分中的 apoC-I。使用质谱法在患有 CAD 的个体的队列中检测到 apoC-I 的新同工型，而预期的 apoC-I 同工型不存在。此外，CAD 队列的 apoC-I 质谱具有卫星峰，表明存在氧化过程的参与。对 CAD 和非 CAD 队列的质谱进一步分析表明，这些新同工型的起源可能是由于遗传突变，这可能会损害 apoC-I 的功能。
相似文献
1
Isoforms of apolipoprotein C-I associated with individuals with coronary artery disease.
Biochem Biophys Res Commun. 2011 Jan 28;404(4):1034-8. doi: 10.1016/j.bbrc.2010.12.105. Epub 2010 Dec 25.
2
Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.
Arterioscler Thromb Vasc Biol. 2017 Jun;37(6):1206-1212. doi: 10.1161/ATVBAHA.117.309007. Epub 2017 May 4.
3
Sialylated isoforms of apolipoprotein C-III and plasma lipids in subjects with coronary artery disease.
Clin Chem Lab Med. 2018 Aug 28;56(9):1542-1550. doi: 10.1515/cclm-2017-1099.
4
Detection of two distinct forms of apoC-I in great apes.
Comp Biochem Physiol Part D Genomics Proteomics. 2010 Mar;5(1):73-9. doi: 10.1016/j.cbd.2009.12.003.
5
HDL in humans with cardiovascular disease exhibits a proteomic signature.
Clin Chim Acta. 2010 Jul 4;411(13-14):972-9. doi: 10.1016/j.cca.2010.03.023. Epub 2010 Mar 20.
6
Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms.
Methods. 2015 Jun 15;81:86-92. doi: 10.1016/j.ymeth.2015.02.020. Epub 2015 Mar 7.
7
Mass spectral study of polymorphism of the apolipoproteins of very low density lipoprotein.
J Lipid Res. 1999 Mar;40(3):543-55.
8
Increased electronegativity of high-density lipoprotein in uremia patients impairs its functional properties and is associated with the risk of coronary artery disease.
Atherosclerosis. 2018 Nov;278:147-155. doi: 10.1016/j.atherosclerosis.2018.09.009. Epub 2018 Sep 13.
9
Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):232-8. doi: 10.1161/ATVBAHA.109.198226. Epub 2009 Nov 12.
10
ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans.
J Lipid Res. 2009 Jul;50(7):1472-8. doi: 10.1194/jlr.P900012-JLR200. Epub 2009 Feb 27.
引用本文的文献
1
Role of apolipoprotein C1 in lipoprotein metabolism, atherosclerosis and diabetes: a systematic review.
Cardiovasc Diabetol. 2022 Dec 5;21(1):272. doi: 10.1186/s12933-022-01703-5.
2
Apolipoprotein C1: Its Pleiotropic Effects in Lipid Metabolism and Beyond.
Int J Mol Sci. 2019 Nov 26;20(23):5939. doi: 10.3390/ijms20235939.
3
Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer.
Cancer Manag Res. 2019 May 29;11:4917-4930. doi: 10.2147/CMAR.S192529. eCollection 2019.
4
Mass Spectrometry-Based Proteomic Study Makes High-Density Lipoprotein a Biomarker for Atherosclerotic Vascular Disease.
Biomed Res Int. 2015;2015:164846. doi: 10.1155/2015/164846. Epub 2015 May 18.
5
Human HDL containing a novel apoC-I isoform induces smooth muscle cell apoptosis.
Cardiovasc Res. 2013 Apr 1;98(1):83-93. doi: 10.1093/cvr/cvt014. Epub 2013 Jan 25.
6
Developing high performance lipoprotein density profiling for use in clinical studies relating to cardiovascular disease.
Anal Chem. 2011 Nov 15;83(22):8524-30. doi: 10.1021/ac2018124. Epub 2011 Oct 18.
本文引用的文献
1
HDL in humans with cardiovascular disease exhibits a proteomic signature.
Clin Chim Acta. 2010 Jul 4;411(13-14):972-9. doi: 10.1016/j.cca.2010.03.023. Epub 2010 Mar 20.
2
Detection of two distinct forms of apoC-I in great apes.
Comp Biochem Physiol Part D Genomics Proteomics. 2010 Mar;5(1):73-9. doi: 10.1016/j.cbd.2009.12.003.
3
A functional polymorphism of apolipoprotein C1 detected by mass spectrometry.
FEBS J. 2006 Oct;273(20):4707-15. doi: 10.1111/j.1742-4658.2006.05473.x. Epub 2006 Sep 18.
4
Metal ion complexes of EDTA as solutes for density gradient ultracentrifugation: influence of metal ions.
Anal Chem. 2005 Nov 1;77(21):7054-61. doi: 10.1021/ac0509657.
5
Molecular mechanism of the blockade of plasma cholesteryl ester transfer protein by its physiological inhibitor apolipoprotein CI.
J Biol Chem. 2005 Nov 11;280(45):38108-16. doi: 10.1074/jbc.M504678200. Epub 2005 Sep 13.
6
Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.
J Lipid Res. 2005 Feb;46(2):297-306. doi: 10.1194/jlr.M400301-JLR200. Epub 2004 Dec 1.
7
Apolipoprotein C-I induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinase.
Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):264-9. doi: 10.1161/01.ATV.0000112036.72200.ac. Epub 2003 Dec 11.
8
Overexpression of apoC-I in apoE-null mice: severe hypertriglyceridemia due to inhibition of hepatic lipase.
J Lipid Res. 2002 Dec;43(12):2136-45. doi: 10.1194/jlr.m200210-jlr200.
9
Apolipoproteins C-I and C-III as important modulators of lipoprotein metabolism.
Curr Opin Lipidol. 2001 Jun;12(3):297-304. doi: 10.1097/00041433-200106000-00009.
10
Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity.
J Biol Chem. 2000 Dec 1;275(48):37504-9. doi: 10.1074/jbc.M007210200.
Zotero 插件